Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | GGT1 | P19440 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3188611 | 0.89 | GABRR1 (0.46) | GABRR1GGT1SMN1; SMN2CPB2NPSR1 | |
| SCHEMBL2232653 | 0.89 | GABRR1 (0.46) | GABRR1GGT1SMN1; SMN2CPB2NPSR1 | |
| SCHEMBL2232656 | 0.89 | GABRR1 (0.46) | GABRR1GGT1SMN1; SMN2CPB2NPSR1 | |
| SCHEMBL7209148 | 0.78 | SMN1; SMN2 (0.42) | GABRR1SMN1; SMN2CPB2NPSR1PLA2G2A | |
| SCHEMBL27698867 | 0.78 | SMN1; SMN2 (0.42) | GABRR1SMN1; SMN2CPB2NPSR1PLA2G2A | |
| SCHEMBL9186768 | 0.77 | SMN1; SMN2 (0.41) | GABRR1SMN1; SMN2MMP1MMP2MMP3 | |
| SCHEMBL4622349 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2NPSR1MAPK1PLA2G2APLA2G5 | |
| SCHEMBL526345 | 0.76 | GABRR1 (0.45) | GABRR1GGT1SMN1; SMN2CPB2 | |
| SCHEMBL3470018 | 0.74 | ALDH1A1 (0.52) | GABRR1GGT1ALDH1A1 | |
| SCHEMBL2153099 | 0.74 | GABRR1 (0.43) | GABRR1GGT1SMN1; SMN2CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168075-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-1896409-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS USEFUL FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006137795-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS USEFUL FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168075-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | CYP46A1, NPC1L1, NPC1 | GABRR1 4827/4885GGT1 1660/4885SMN1; SMN2 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.